General
Preferred name
BENZTHIAZIDE
Synonyms
Aquatag ()
Lemazide ()
Dihydrex ()
Benzthiazide ()
Benzothiazide ()
Urese ()
EXNA ()
Fovane ()
Benztiazida ()
NSC-755902 ()
P&D ID
PD002458
CAS
91-33-8
Tags
available
drug
Approved by
FDA
First approval
1960
Drug indication
High blood pressure
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Benzthiazide is a long-acting diuretic[1] and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells[2].
DESCRIPTION Benzthiazide is a thiazide diuretic. It is no longer available in the US or UK, but marketing may be authorised by other national approval agencies. (GtoPdb)
DESCRIPTION Benzthiazide is a long-acting diuretic and a hypertension agent. It is an inhibitor of carbonic anhydrase. (Enamine Bioactive Compounds)
DESCRIPTION Benzthiazide (Lemazide) is used in the therapy of edema and hypertension. Like other thiazides, benzthiazide accelerates water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. (TargetMol Bioactive Compound Library)
Compound Sets
20
ChEMBL Approved Drugs
CHEMBL1201039
ChEMBL Drugs
CHEMBL1201039
DrugBank
DB00562
DrugBank Approved Drugs
DB00562
DrugCentral
332
DrugCentral Approved Drugs
332
DrugMAP
DMQWZ0H
DrugMAP Approved Drugs
DMQWZ0H
DrugMatrix
Enamine Bioactive Compounds
EBC-07702
Enamine BioReference Compounds
Guide to Pharmacology
7125
MedChem Express Bioactive Compound Library
HY-B1424
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
benzthiazide
TargetMol Bioactive Compound Library
T0782
The Spectrum Collection
Withdrawn 2.0
276
External IDs
33
Properties
(calculated by RDKit )
Molecular Weight
430.98
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
2.24
TPSA
118.69
Fraction CSP3
0.13
Chiral centers
0.0
Largest ring
6.0
QED
0.75
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Carbonic Anhydrase
ATC
G01AE10
Pathway
Metabolism
Metabolic Enzyme/Protease
Therapeutic Class
Antihypertensive Agents
Source data